New drug approach offers hope for patients with recurrent aggressive cancers

A new treatment for endometrial cancer, sacituzumab tirumotecan, demonstrated strong potential in a Phase 3 clinical trial, meeting its primary endpoints of overall survival and progression-free survival. The trial involved 776 patients with advanced or recurrent endometrial cancer. The results show promise for addressing a critical unmet need for certain patients.